戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1   It cleaved penicillin and was inhibited by sulbactam.
2  inhibited by beta-lactamase inhibitor, i.e. sulbactam.
3 and 71 patients were treated with Ampicillin-Sulbactam.
4 ctam is superior to both clavulanic acid and sulbactam.
5  as well as on the beta-lactamase inhibitor, sulbactam.
6 ination of CMS, a carbapenem, and ampicillin-sulbactam.
7 he same time resistant to I/R and ampicillin/sulbactam.
8  reports on SBL inhibition by tazobactam and sulbactam.
9 s to ampicillin (100 versus 20%), ampicillin-sulbactam (100 versus 13%), vancomycin (100 versus 57%),
10  cultures [53.1%]; institution B: ampicillin-sulbactam, 9 [69.2%]; and institution C: penicillin, 32
11 -lactamase-inhibiting antibiotics ampicillin-sulbactam (A/S) and amoxicillin-clavulanic acid (A/C) fo
12 amoxicillin-clavulanate (AUG) and ampicillin-sulbactam (A/S) susceptibility testing by three differen
13 ure of the inhibitor preacylation complex of sulbactam, a clinical beta-lactamase inhibitor, bound in
14 C, and D serine beta-lactamases and restores sulbactam activity against multidrug-resistant ABC.
15 azole, cefotetan, ampicillin, and ampicillin-sulbactam all promoted persistent high levels of stool V
16 losporin, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate.
17 bited increased susceptibility to ampicillin/sulbactam, an important difference compared to ampicilli
18                                        Using sulbactam and 6,6-dideuterated sulbactam we follow these
19  despite treatment with high-dose ampicillin-sulbactam and cefiderocol.
20                               The ampicillin/sulbactam and ceftazidime/avibactam combinations demonst
21   The pharmacodynamic activity of ampicillin/sulbactam and ceftazidime/avibactam was evaluated agains
22 r both (AMA205) were resistant to ampicillin/sulbactam and ceftazidime/avibactam.
23  structures of the beta-lactamase inhibitors sulbactam and clavulanic acid bound to the deacylation-d
24                       Band broadening in the sulbactam and clavulanic acid inter-mediates reflected a
25 mately twice as much enamine intermediate as sulbactam and clavulanic acid, which correlates with its
26  A beta-lactamases by the similar inhibitors sulbactam and clavulanic acid.
27 ases in resistance were noted for ampicillin-sulbactam and clindamycin, while significant decreases i
28 relationship associated with the activity of sulbactam and durlobactam established in nonclinical inf
29                                              Sulbactam and durlobactam were detected in CSF at both t
30 tablish the MIC test method, combinations of sulbactam and durlobactam were evaluated using a panel o
31 ses because it assesses the activity of both sulbactam and durlobactam with clear endpoints.
32      The patient was treated with ampicillin-sulbactam and metronidazole intravenously for 3 wks, fol
33  by sulfone beta-lactamase inhibitors (i.e., sulbactam and tazobactam) than CMY-2.
34                               In contrast to sulbactam and tazobactam, the reactions between oxacilli
35 phenotype, we investigated the activities of sulbactam and two novel penem beta-lactamase inhibitors
36 eta-lactamase and the inhibitors tazobactam, sulbactam, and clavulanic acid are followed in single cr
37                                  Tazobactam, sulbactam, and clavulanic acid are the only beta-lactama
38  clinically relevant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta-lactamase (
39  that for small ligands, such as tazobactam, sulbactam, and clavulanic acid, the positioning of the l
40 the mechanism-based inactivators tazobactam, sulbactam, and clavulanic acid.
41 ve inhibitory activities of clavulanic acid, sulbactam, and tazobactam against clinically important b
42 0G variant that reacts with clavulanic acid, sulbactam, and tazobactam in solution, but lacks the cha
43 by the clinical inhibitors (clavulanic acid, sulbactam, and tazobactam), but the prevalence of inhibi
44 gents used in combination, such as colistin, sulbactam, and the tetracyclines, and offer clinical pea
45 he clinically used inhibitors tazobactam and sulbactam are effective in the inhibition of activity of
46 tients receiving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P =
47  with Enterobacter cloacae versus ampicillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavu
48 n most clinical scenarios, a dose-optimized, sulbactam-based regimen is recommended with the addition
49  on both systems (exceptions were ampicillin-sulbactam, cefoxitin, minocycline, and nitrofurantoin).
50 dies of S130G SHV inhibited with tazobactam, sulbactam, clavulanic acid, and 2'-glutaroxy penem sulfo
51 aximal populations at 10, 22, and 29 min for sulbactam, clavulanic acid, and tazobactam, respectively
52 ation demonstrated that high-dose ampicillin/sulbactam combinations were required to achieve 4-6 log1
53 demonstrated 70 and 88 +/- 3 Da fragments of sulbactam covalently attached to the beta-lactamase.
54                                   Ampicillin-sulbactam disks containing either 10 microg of each drug
55 statin, penicillin G, ampicillin, ampicillin/sulbactam, doxycycline, and minocycline; acceptable (90%
56 y to obtaining the preacylation complex with sulbactam due to further decreased reactivity toward sub
57                           When combined with sulbactam, durlobactam effectively restores the suscepti
58 y CRAB meningitis with the administration of sulbactam-durlobactam and meropenem and highlights the n
59           On day 13, she was transitioned to sulbactam-durlobactam and meropenem; 4 subsequent CSF cu
60          Studies were conducted to establish sulbactam-durlobactam antimicrobial susceptibility testi
61                                            A sulbactam-durlobactam broth MIC QC range of 0.5/4-2/4 ug
62 ed pre-dose and 3-hours post initiation of a sulbactam-durlobactam infusion.
63                                              Sulbactam-durlobactam is a beta-lactam/beta-lactamase in
64                                              Sulbactam-durlobactam is a beta-lactam/beta-lactamase in
65                                              Sulbactam-durlobactam is a pathogen-targeted beta-lactam
66                                       Should sulbactam-durlobactam receive regulatory approval, recom
67                                              Sulbactam-durlobactam, a unique beta-lactam and a beta-l
68                             After 14 days of sulbactam-durlobactam, she was cured of infection.
69 oped beta-lactam agents like cefiderocol and sulbactam-durlobactam, which have demonstrated contrasti
70 tatin-relebactam, meropenem-vaborbactam, and sulbactam-durlobactam.
71                               Similarly, the sulbactam/durlobactam 10/10 ug disk concentration showed
72               These newer BL/BLIs, including sulbactam/durlobactam, have an array of activity against
73 t is demonstrated that with the exception of sulbactam, each compound forms observable trans-enamine
74 transferred ceftazidime resistance or showed sulbactam enhancement of oxyimino-beta-lactam susceptibi
75    One of the most promising combinations is sulbactam-ETX2514, whose potent antibacterial activity,
76                      The clinical utility of sulbactam for the treatment of contemporary Acinetobacte
77 t species, with SHV-1, while clavulanate and sulbactam form a mixture of trans-enamine and two labile
78                         The MBM incorporated sulbactam hydrolysis by NDM-1 and OXA23 enzymes, along w
79  running the reactions with the two forms of sulbactam in parallel, provides an element of control an
80 ce, however, has eroded the effectiveness of sulbactam in the treatment of this pathogen.
81                                              Sulbactam inhibits the enzyme competitively and reversib
82 he prophylaxis group received 1 g ampicillin-sulbactam intravenously at anesthesia.
83                                     Although sulbactam is a beta-lactamase inhibitor of a subset of A
84                                              Sulbactam is a first-generation, narrow-spectrum beta-la
85                                              Sulbactam is a mechanism-based inhibitor of beta-lactama
86                                   The intact sulbactam is positioned in the active site such that its
87 n combined with durlobactam, the activity of sulbactam is restored against this problematic pathogen.
88 ceftriaxone plus metronidazole or ampicillin/sulbactam) is appropriate.
89 y against a class C beta-lactamase than does sulbactam itself.
90 ith penicillin G, ampicillin, and ampicillin-sulbactam MICs and inhibition zones on penicillin (2-U)
91 am forms a larger population of enamine than sulbactam or clavulanic acid does and that tazobactam's
92       Few enamine-like species are formed by sulbactam or tazobactam with this enzyme.
93  either bactericidal antibiotics (ampicillin/sulbactam) or placebo (saline).
94                     Resistance to ampicillin-sulbactam ranged from 25% of A. schubertii strains to 10
95 tinguish tazobactam from clavulanic acid and sulbactam, respectively.
96                   Avibactam notably enhanced sulbactam's activity.
97 ss spectrometry analysis of SHV inhibited by sulbactam showed that SHV-1 beta-lactamase was unmodifie
98                   Namely, compared to SHV-1, sulbactam shows significantly smaller populations of cis
99 um with metronidazole, and ampicillin sodium-sulbactam sodium, respectively.
100 ked in 5 mM tazobactam, clavulanic acid, and sulbactam solutions, respectively.
101 ium tuberculosis enzyme BlaC is inhibited by sulbactam (SUB).
102 hree FDA-approved beta-lactamase inhibitors: sulbactam, tazobactam, and clavulanate.
103    It is proposed that for the unsubstituted sulbactam the conversion from imine to enamine, which in
104                        For the 6,6-dideutero-sulbactam the same step involves breaking a C-D bond, wh
105 s us to conclude that, for the unsubstituted sulbactam, the formation of the cross-linked intermediat
106                          Compared to that of sulbactam, the kcat/kinact values of penems for SHV-1 an
107                            For the unlabeled sulbactam, the Raman data show the presence of an acryla
108 od susceptibilities but only with ampicillin-sulbactam, ticarcillin-clavulanate, and/or clindamycin.
109 acillin, piperacillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefoteta
110  a three-day treatment regimen of Ampicillin-Sulbactam to that of a three-day regimen of Ertapenem in
111 hibitors of class A beta-lactamases, such as sulbactam, undergo a complex series of chemical reaction
112 nvestigated the mechanisms of tazobactam and sulbactam using mass spectrometry under denaturing and n
113 and DD were unacceptably high for ampicillin-sulbactam (VM error, 9.8%; minor [m] error, 16.1%), pipe
114 -S, -Q, and -L) variants revealed the Ki for sulbactam was significantly elevated for the R244 varian
115                               Ampicillin and sulbactam was the most common systemic antibiotic prophy
116         Using sulbactam and 6,6-dideuterated sulbactam we follow these alternate paths in WT and E166
117 Li), i.e., the penam sulfones tazobactam and sulbactam, which are mechanism-based inhibitors working
118       MIC testing with doubling dilutions of sulbactam with a fixed concentration of 4 ug/mL of durlo

 
Page Top